Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

(2021) Thomas Bachelot et al.   NATURE MEDICINE

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

(2021) A. Brufsky et al.   ANNALS OF ONCOLOGY

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

(2021) Leisha A Emens et al.   JNCI-Journal of the National Cancer Institute

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

(2021) Eric P Winer et al.   LANCET ONCOLOGY

Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis

(2021) Michal Sternschuss et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

(2020) Rita Nanda et al.   JAMA Oncology

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

(2020) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Inhibitor‐Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis

(2020) Virginie Grouthier et al.   ONCOLOGIST

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

(2020) S. Paluch-Shimon et al.   ANNALS OF ONCOLOGY

Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer

(2020) Nicola Gaynor et al.   SEMINARS IN CANCER BIOLOGY

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

(2020) Elizabeth A Mittendorf et al.   LANCET

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

(2020) Leisha A Emens et al.   LANCET ONCOLOGY

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

(2020) Sara M. Tolaney et al.   JAMA Oncology

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study

(2019) S Loibl et al.   ANNALS OF ONCOLOGY

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Peter Schmid et al.   LANCET ONCOLOGY

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

(2018) Romualdo Barroso-Sousa et al.   JAMA Oncology

Endocrine toxicity of cancer immunotherapy targeting immune checkpoints

(2018) Lee-Shing Chang et al.   ENDOCRINE REVIEWS

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab

(2017) Petros Fessas et al.   SEMINARS IN ONCOLOGY

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.

(2017) M. K. Callahan et al.   JOURNAL OF CLINICAL ONCOLOGY

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

(2016) H. L. McArthur et al.   CLINICAL CANCER RESEARCH

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

(2013) S A Quezada et al.   BRITISH JOURNAL OF CANCER

PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts

(2013) Elaine M. Beller et al.   PLOS MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE